GPX4 and amyotrophic lateral sclerosis: Third, clinical translation should include establishing multicenter ALS biobanks to validate associations between biomarkers such as ACSL4 and GPX4 and clinical measures including ALSFRS-R scores and survival, and conducting combined trials of ferroptosis inhibitors with mitochondrial protectants to evaluate therapeutic benefit in sporadic ALS.